查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529670

數位生物標記市場規模、佔有率、趨勢分析報告：按類型、按臨床業務、按治療領域、按最終用途、按地區、按細分市場、預測，2024-2030 年

Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile Based Applications), By Clinical Practice, By Therapeutic Area, By End-use (Healthcare Companies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

數位生物標記市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球數位生物標記市場規模將達到139.7億美元，2024年至2030年複合年成長率為22.7%。

這種成長的推動因素包括醫療保健相關行動應用程式和設備的普及、人們對各種治療應用的認知提高、智慧型手機的使用增加以及新型穿戴式技術的推出。根據 2021 年Accenture健康與生命科學體驗研究，26% 的美國居民透過採用醫療保健應用程式和設備，獲得醫療保健服務的機會得到了改善。

此外，由於 COVID-19 爆發帶來的巨大困難，政府機構表示有興趣開發基於數位生物標記的藥物。例如，2022 年 3 月，Astra Zeneca與英國醫療科技公司 Huma Therapeutics 合作，開發用於多種治療疾病的軟體即醫療設備 (SaMD)伴同性應用程式。這些應用程式結合了預測演算法、數位生物標記和現實世界資料。

藥物研究成本的上升和相對較低的成功率正在推動數位生物標記（DBM）的快速創建。該領域的DBM將有助於專注於特定的分散臨床研究領域，例如早發性阿茲海默症和失智症，從而減少藥物開發時間、失敗率和成本。根據一家名為 healthxl 的數位解決方案公司的部落格報導，數位醫學研究所 (DiME) 最近匯集了禮來 (Eli Lilly)、默克 (Merck) 和百健 (Biogen) 等頂級製藥公司，為失智症和阿茲海默症。這樣做是為了解決評估新治療方法對人類的有效性的問題，並減少用於研究和開發新治療方法的時間和金錢。

世界各地的地方政府正在透過實施意識計劃和投資數位健康發展來支持生物標記的採用。根據加州大學戴維斯分校醫學院2022年發表的報導，加州大學戴維斯分校健康中心實施的數位健康公平計畫獲得了聯邦政府170萬美元的資助。這筆聯邦資金預計將有助於開發一個區域數位公共衛生平台，該平台可以改善北加州和沙加緬度弱勢群體獲得醫療保健的機會。

AliveCor Inc.、Empatica, Inc.、Huma 和 VivoSense 等新興企業正在採取收購、聯盟、合作夥伴關係和新產品發佈等策略，預計這些策略將在預測期內推動市場成長。例如，2023 年 1 月，數位健康公司 Huma 宣布收購 Alcedis，以擴大其在數位臨床試驗領域的能力。此次收購的目的是在開發過程的各個階段開發醫療保健解決方案。

數位生物標記市場報告亮點

  • 按類型分類，由於醫療保健用途的新型穿戴裝置的出現，穿戴式裝置在 2023 年佔據最大的市場佔有率，達到 39.5%。隨著政府當局核准新型穿戴式設備，市場對新型穿戴裝置的需求預計將會增加。
  • 根據臨床實踐，診斷數位生物標記在 2023 年佔據最大市場佔有率，達到 32.4%。診斷數位生物標記是源自穿戴式裝置、行動應用程式和醫療設備等數位技術的健康狀況或疾病的量化指標。分析資料、行為、資料、資料和資料報告的資料可以實現早期檢測、準確診斷和個人化治療。這些創新工具透過改善患者治療結果並促進遠端監測和疾病管理，為醫療保健的進步做出了貢獻。
  • 按治療領域來看，由於治療應用的增加和全球心血管疾病的增加，心血管疾病領域在 2023 年以 19.8% 的佔有率佔據市場主導地位。
  • 以最終用途分類，醫療保健公司在 2023 年佔據最大的市場佔有率，達到 50.1%。這是因為醫療保健公司致力於將數位測量整合到臨床護理和研究中。
  • 北美地區佔據主導地位，2023 年收益佔有率為 58.4%。這是由於主要市場參與者的強大存在、重要的產品發布以及對研發生物標記的投資不斷增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章數位生物標記市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望。
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 數位生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章數位生物標記市場：按類型估計和趨勢分析

  • 2023 年和 2030 年按類型分類的市場佔有率
  • 細分儀表板
  • 按類型分類的全球數位生物標記市場展望
  • 2018-2030年市場規模及預測及趨勢分析

第5章數位生物標記市場：臨床業務的估計和趨勢分析

  • 2023年及2030年按臨床業務分類的市場佔有率佔有率
  • 細分儀表板
  • 按臨床業務分類的全球數位生物標記市場展望
  • 2018-2030年市場規模及預測及趨勢分析

第6章數位生物標記市場：按治療領域估計和趨勢分析

  • 2023 年和 2030 年按治療領域市場佔有率
  • 細分儀表板
  • 按治療領域分類的全球數位生物標記市場前景
  • 2018-2030年市場規模及預測及趨勢分析

第7章數位生物標記市場：最終用戶的估計和趨勢分析

  • 2023 年和 2030 年按最終用戶類型市場佔有率
  • 細分儀表板
  • 最終用戶的全球數位生物標記市場前景
  • 2018-2030年市場規模及預測及趨勢分析

第8章數位生物標記市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 北美：SWOT 分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT 分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT 分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT 分析
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 中東/非洲：SWOT 分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • Company Market Position Analysis, 2023
    • ActiGraph LLC
    • AliveCor Inc.
    • Koneksa
    • Altoida Inc.
    • Amgen Inc.
    • Biogen Inc.
    • Empatica Inc.
    • Vivo Sense
    • IXICO plc
    • Adherium Limited
    • Vivo Sense
    • Neurotrack Technologies, Inc.
    • Aural Analytic
    • Huma Therapeutics
    • Sonde Health, Inc.
    • Clario
    • Imagene AI
    • Brainomix
    • Kinsa Inc.
Product Code: GVR-4-68039-989-3

Digital Biomarkers Market Growth & Trends:

The global digital biomarkers market size is expected to reach USD 13.97 billion by 2030, growing at a CAGR of 22.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising adoption of mobile applications & devices related to healthcare, and rising awareness regarding the wide therapeutic applications, increased utilization of smartphones, and the introduction of novel wearable technologies. According to Accenture Health and Life Sciences Experience Survey in 2021, 26% of the people living in the U.S. experienced enhanced access to healthcare services with the adoption of healthcare applications and devices.

Further, governmental organizations have expressed interest in creating digital biomarker-based medication due to the significant hardship brought on by the Covid-19 outbreak. For instance, in March 2022, AstraZeneca teamed up with UK-based medical technology company Huma Therapeutics to develop Software as a Medical Device (SaMD) companion applications for a range of therapeutic diseases. These applications combined predictive algorithms, digital biomarkers, and real-world data.

The rising cost of drug research, combined with its low relative success rate, is fuelling rapid creation of digital biomarkers (DBMs). DBMs in this field assist in focusing on particular decentralized clinical study areas, including early-onset Alzheimer's or dementia, thereby lowering the time, failure rate of drug development, and cost. According to a blog post by a digital solutions company called healthxl, the Digital Medicine Society (DiME) lately brought together top pharmaceutical companies, including Eli Lilly, Merck, and Biogen, to ascertain a set of core standard digital endpoints for dementia and Alzheimer's disease. This was done to solve the issue of assessing the efficacy of new therapies in human subjects as well as to reduce time & money spent on research and development of new remedies.

Regional governments across the globe are supporting the adoption of biomarkers by conducting awareness programs and investing in the development of digital health. According to an article published by the UC Davis School of Medicine in 2022, the Digital Health Equity Program conducted by UC Davis Health received funding of USD 1.7 million from the federal government. This government funding is expected to contribute to the development of a regional digital public health platform capable of enhancing access to healthcare facilities for vulnerable populations in Northern California and Sacramento.

Emerging players, such as AliveCor Inc, Empatica, Inc., Huma, and VivoSense, are adopting strategies such as acquisitions, collaborations, partnerships, and new product launches is anticipated to drive the market growth over the forecast period. For instance, in January 2023, Huma, a digital health company, announced the acquisition of Alcedis to expand its capabilities in the digital clinical trial space. The goal of this acquisition is to develop healthcare solutions across various stages of development processes.

Digital Biomarkers Market Report Highlights:

  • Based on type, wearables held the largest market share of 39.5% in 2023, owing to the emergence of new wearables for healthcare purposes. It is anticipated that the market demand for new wearable devices is expected to increase because of government authorities approving new wearable devices
  • Based on clinical practice, the diagnosis digital biomarkers held the largest market share of 32.4% in 2023. Diagnosis digital biomarkers are quantifiable indicators of health conditions or diseases, derived from digital technologies such as wearables, mobile apps, and medical devices. They enable early detection, accurate diagnosis, and personalized treatment by analyzing physiological, behavioral, biochemical, imaging, and patient-reported data. These innovative tools contribute to the advancement of healthcare by improving patient outcomes and facilitating remote monitoring and disease management
  • Based on therapeutic area,the cardiovascular disease segment dominated the market with a share of 19.8% in 2023, owing to the growing number of therapeutic applications and increasing incidences of cardiovascular disorders globally
  • Based on end use, the healthcare companies held the largest market share of 50.1% in 2023, owing to the fact that healthcare companies have been working toward integrating digital measurements across the spectrum of clinical care & research
  • North America dominated the market and accounted for a revenue share of 58.4% in 2023, owing to the strong presence of leading market players, significant product launches, and an increase in investments in the R&D biomarkers

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Clinical Practice
    • 1.2.3. Therapeutic Area
    • 1.2.4. End User
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Clinical practice outlook
    • 2.2.3. Therapeutic Area Outlook
    • 2.2.4. End User outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Digital Biomarker Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Digital Biomarker Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Digital Biomarker Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Digital Biomarker Market Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Wearable
      • 4.4.1.1. Wearable market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Mobile based applications
      • 4.4.2.1. Mobile based applications market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Sensors
      • 4.4.3.1. Sensors market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Digital Biomarker Market: Clinical Practice Estimates & Trend Analysis

  • 5.1. Clinical Practice Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Digital Biomarker Market Clinical Practice Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Diagnostic digital biomarkers
      • 5.4.1.1. Diagnostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Monitoring digital biomarkers
      • 5.4.2.1. Monitoring digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Predictive and Prognostic digital biomarkers
      • 5.4.3.1. Predictive and Prognostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others (Safety, Pharmacodynamics/ Response, Susceptibility)
      • 5.4.4.1. Others (Safety, Pharmacodynamics/ Response, Susceptibility) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Digital Biomarker Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Therapeutic Area Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Digital Biomarker Market by Therapeutic Area Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cardiovascular and metabolic disorders (CVMD)
      • 6.4.1.1. Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Respiratory diseases
      • 6.4.2.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Psychiatric disorders
      • 6.4.3.1. Psychiatric disorders market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Sleep & movement disease
      • 6.4.4.1. Sleep & movement disease market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Neurological disorders
      • 6.4.5.1. Neurological disorders market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Musculoskeletal disorders
      • 6.4.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Others (Diabetes, Pain Management)
      • 6.4.7.1. Others (Diabetes, Pain Management) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Digital Biomarker Market: End User Estimates & Trend Analysis

  • 7.1. End User Type Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Digital Biomarker Market by End User Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Healthcare companies
      • 7.4.1.1. Healthcare companies market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Healthcare Providers
      • 7.4.2.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Healthcare Providers
      • 7.4.3.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Others (Patient, caregivers)
      • 7.4.4.1. Others (Patient, caregivers) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Digital Biomarker Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Company Market Position Analysis, 2023
    • 9.3.2. ActiGraph LLC
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. AliveCor Inc.
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Koneksa
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Altoida Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Amgen Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Biogen Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Empatica Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Vivo Sense
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. IXICO plc
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Adherium Limited
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Vivo Sense
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Neurotrack Technologies, Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Aural Analytic
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Huma Therapeutics
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Sonde Health, Inc.
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. Clario
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Product benchmarking
      • 9.3.17.4. Strategic initiatives
    • 9.3.18. Imagene AI
      • 9.3.18.1. Company overview
      • 9.3.18.2. Financial performance
      • 9.3.18.3. Product benchmarking
      • 9.3.18.4. Strategic initiatives
    • 9.3.19. Brainomix
      • 9.3.19.1. Company overview
      • 9.3.19.2. Financial performance
      • 9.3.19.3. Product benchmarking
      • 9.3.19.4. Strategic initiatives
    • 9.3.20. Kinsa Inc.
      • 9.3.20.1. Company overview
      • 9.3.20.2. Financial performance
      • 9.3.20.3. Product benchmarking
      • 9.3.20.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 6 North America digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 7 North America digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 9 U.S digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 10 U.S digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 11 U.S digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Canada digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Canada digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 14 Canada digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 15 Canada digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Mexico digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 14 Mexico digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 15 Mexico digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Europe digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 17 Europe digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 18 Europe digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 19 Europe digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 20 Europe digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 U.K digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 U.K digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 23 U.K digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 24 U.K digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 France digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 France digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 23 France digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 24 France digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Germany digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 26 Germany digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 27 Germany digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 28 Germany digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Denmark digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 30 Denmark digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 31 Denmark digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 32 Denmark digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Italy digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 34 Italy digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 35 Italy digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 36 Italy digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Sweden digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 38 Sweden digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 39 Sweden digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 40 Sweden digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 China digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 47 China digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 48 China digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 49 China digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Japan digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 51 Japan digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 52 Japan digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 53 Japan digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 India digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 55 India digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 56 India digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 57 India digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 58 Australia digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 59 Australia digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 60 Australia digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 61 Australia digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 South Korea digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 63 South Korea digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 64 South Korea digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 65 South Korea digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Latin America digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 67 Latin America digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 68 Latin America digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 69 Latin America digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 70 Latin America digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Brazil digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 72 Brazil digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 73 Brazil digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 74 Brazil digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Argentina digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 73 Argentina digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 74 Argentina digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 MEA digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 80 MEA digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 81 MEA digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 82 MEA digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 83 MEA digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 South Africa digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 South Africa digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 86 South Africa digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 87 South Africa digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 89 UAE digital biomarker market, by type, 2018 - 2030 (USD Million)
  • Table 90 UAE digital biomarker market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 91 UAE digital biomarker market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 92 UAE digital biomarker market, by end user, 2018 - 2030 (USD Million)
  • Table 93 Kuwait digital biomarker market, by type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait digital biomarker market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 95 Kuwait digital biomarker market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 96 Kuwait digital biomarker market, by end user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Digital Biomarker: market outlook
  • Fig. 9 Digital Biomarker competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook.
  • Fig. 12 Digital Biomarker driver impact
  • Fig. 13 Digital Biomarker restraint impact
  • Fig. 14 Digital Biomarker strategic initiatives analysis
  • Fig. 16 Digital Biomarkers Market: By Type Movement Analysis
  • Fig. 17 Wearable market estimates and forecasts, 2018 - 2030
  • Fig. 18 Mobile based applications market estimates and forecasts, 2018 - 2030
  • Fig. 19 Sensors market estimates and forecasts, 2018 - 2030
  • Fig. 20 Others market estimates and forecasts, 2018 - 2030
  • Fig. 21 Digital Biomarkers Market: By Clinical Practice Movement Analysis
  • Fig. 22 Diagnostic digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Monitoring digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Predictive and prognostic digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Others digital biomarker market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Digital Biomarkers Market: By Therapeutic Area Movement Analysis
  • Fig. 27 Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Psychiatric disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Sleep & movement disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Neurological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Musculoskeletal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Digital Biomarkers Market: By End-Use Movement Analysis
  • Fig. 35 Healthcare companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Healthcare providers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Payers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 Regional outlook, 2023 & 2030
  • Fig. 41 North America digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 42 U.S. digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 43 Canada digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 43 Mexico digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 44 Europe digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 45 U.K. digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 45 France digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 46 Germany digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 45 Spain digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 47 Denmark digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 47 Sweden digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 47 Norway digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 48 Italy digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 49 Sweden digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 50 Asia Pacific digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 51 Japan digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 52 China digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 53 India digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 54 South Korea digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 55 Australia digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 56 Latin America digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 57 Brazil digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 58 Argentina digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 59 MEA digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 60 South Africa digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 61 Saudi Arabia digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 62 UAE digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 63 Kuwait digital biomarkers market estimates and forecasts, 2018 - 2030